| SEC For  |   |            |   |        |   |  |  |        | -0   |        |                             |   | <b></b>                                | 001011   |  |  |  |  |  |
|--|---|------------|---|--------|---|--|--|--------|--|--------|-----------------------------|---|--|--|--|--|--|--|--|
| FORM 4 UNITED  |   |            |   | 51/    | STATES SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549 |  |  |        |  |        |                             |   |  |  |  | OMB APPROVAL   |  |  |  |
| Section 16. Form 4 or Form 5<br>obligations may continue. See                        |   |            |   |        |   |  | T OF CHANGES IN BENEFICIAL OWNERS                          |        |  |        |                             |   |  |  |  | OMB Number: 3235-0287<br>Estimated average burden<br>hours per response: 0.5 |  |  |  |
| 1. Name and Address of Reporting Person <sup>*</sup><br>Tourangeau Greg              |   |            |   |        |   | <u>Fulcrum Therapeutics, Inc.</u> [FULC ] (C                   |  |        |  |        |                             |   |  |  | of Reportin<br>cable)<br>or<br>(give title   | 10%  |  |  |  |
| (Last) (First) (Middle)<br>C/O FULCRUM THERAPEUTICS, INC.                            |   |            |   |        |   | 3. Date of Earliest Transaction (Month/Day/Year)<br>01/26/2024 |  |        |  |        |                             |   |  | X Oncer (specify<br>below) below)<br>Vice President, Finance   |  |  |  |  |  |
| 26 LANDSDOWNE STREET   |   |            |   |        | - 4.1   |  |  |        |  |        |                             |   |  | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person |  |  |  |  |  |
| (Street)<br>CAMBRIDGE MA 02139   |   |            |   |        |   |  |  |        |  |        |                             |   |  |  |  | d by More than One Reporting   |  |  |  |
| (City) (State) (Zip)   |   |            |   |        |   | Rule 10b5-1(c) Transaction Indication                          |  |        |  |        |                             |   |  |  |  |  |  |  |  |
|  |   | Tat        | ole I - Nor   | n-Deri | vativ   | satis  | fy the affirr  | mative | e defense co   | nditic | ons of Rule 1               | 0b5-1(c). S   | e Instructio                           | n 10.  |  | plantin  |  |  |  |
| Table I - Non-Deriva   1. Title of Security (Instr. 3)   2. Transa Date<br>(Month/E) |   |            |   |        | sactior   | n<br>ear)  | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year |        | 3.<br>Transaction<br>Code (Instr. 5)                           |        | 4. Securi<br>Disposed<br>5) | ities Acquired (A) or<br>d Of (D) (Instr. 3, 4 and  |  | 5. Amount of   |  | Form<br>(D) o  | n: Direct<br>r Indirect<br>nstr. 4)                                      | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)  |  |
|  |   |            | Table II -  |        |   |  |  |        | uired, D   | isp    |                             |   | eficially                              |  | and 4)   |  |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                                  | ive Conversion Date<br>y or Exercise (Month/Day/Year) |            | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |        | 4.<br>Transaction<br>Code (Instr.<br>8)                             |  |  |        | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |        |                             | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)  | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) |  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |   |            |   |        | Code  | v  | (A)  | (D)    | Date<br>Exercisab  |        | Expiration<br>Date          | Title   | Amount<br>or<br>Number<br>of<br>Shares |  |  |  |  |  |  |
| Stock<br>Option<br>(right to<br>buy)   | \$6.95  | 01/26/2024 |   |        | А   |  | 83,820   |        | (1)  |        | 01/25/2034                  | Common<br>Stock   | 83,820                                 | \$0.00   | 83,82  | :0   | D  |  |  |
| Stock<br>Option<br>(right to<br>buy)   | \$6.95  | 01/26/2024 |   |        | Α   |  | 10,000   |        | (2)  |        | 01/25/2034                  | Common<br>Stock   | 10,000                                 | \$0.00   | 10,00  | 0  | D  |  |  |

## Explanation of Responses:

1. This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date.

2. This option was granted on January 26, 2024 and is scheduled to vest in equal yearly installments over two years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date.

/s/ Gregory Tourangeau

\*\* Signature of Reporting Person

01/30/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.